Welcome to our dedicated page for Oculis Holding Ordinary shares news (Ticker: $OCS), a resource for investors and traders seeking the latest updates and insights on Oculis Holding Ordinary shares stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Oculis Holding Ordinary shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Oculis Holding Ordinary shares's position in the market.
Oculis reported its Q1 2024 financial results and provided updates on its clinical programs, including the initiation of the second OCS-01 Phase 3 DIAMOND-2 trial in Diabetic Macular Edema and completion of enrollment in OCS-02 Phase 2b RELIEF trial in Dry Eye Disease. The company raised $59 million in a direct equity offering, listed on Nasdaq Iceland Main Market, and strengthened its executive team. Financially, Oculis had a cash position of CHF 79.9 million, with research and development expenses of CHF 10.9 million. The company reported a net loss of CHF 16.1 million for Q1 2024. Oculis is on track with its clinical milestones, with topline results anticipated in the second and fourth quarters of 2024.
Oculis has completed enrollment in the Phase 2 ACUITY trial for OCS-05 in patients with Acute Optic Neuritis, with topline results expected in Q4 2024. The drug has received orphan drug designation in the US and Europe for AON. The trial aims to assess the safety and tolerability of OCS-05, offering potential neuroprotective benefits in ophthalmic diseases.
Oculis Holding AG has published an invitation to its 2024 Annual General Meeting, scheduled for May 29, 2024, in Zug, Switzerland. The meeting details and materials are available on the company's website.
Oculis Holding AG (Nasdaq: OCS; XICE: OCS) announced that its management will be presenting at the Bank of America Healthcare Conference in Las Vegas on May 14-16, 2024. Riad Sherif, M.D., the CEO, will deliver a company presentation on May 15th at 11:20 am PT. Interested investors can schedule one-on-one meetings through their Bank of America representative.
Oculis Holding AG has published an invitation to its 2024 Annual General Meeting to be held on May 29, 2024, in Zug, Switzerland. The meeting details and materials are available on the company's website.
